Category: 20327-23-5

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

To a stirred solution of 135 1-fluoro-4-nitro-benzene (500 mg, 3.54 mmol) and 213 1-cyclopropylpiperazine (536 mg, 4.25 mmol) in 10 mL of 6 ethanol was added 27 DIPEA (913 mg, 7.08 mmol) and stirred at reflux for 12 h. After completion of reaction, solvent was removed under reduced pressure, diluted with water (20 mL) and extracted with CH2Cl2 (20 mL×3). Combined organic layer was washed with brine solution, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford crude product which was washed with diethyl ether and dried to afford 214 1-cyclopropyl-4-(4-nitrophenyl)piperazine (450 mg). (0348) LCMS: 248 [M+1]+

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; giraFpharma LLC; Chakravarty, Sarvajit; PHAM, Son Minh; Kankanala, Jayakanth; AGARWAL, Anil Kumar; PUJALA, Brahmam; SONI, Sanjeev; ARYA, Satish K.; PALVE, Deepak; KUMAR, Varun; (360 pag.)US2019/106436; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

To a stirred solution of 135 1-fluoro-4-nitro-benzene (500 mg, 3.54 mmol) and 213 1-cyclopropylpiperazine (536 mg, 4.25 mmol) in 10 mL of 6 ethanol was added 27 DIPEA (913 mg, 7.08 mmol) and stirred at reflux for 12 h. After completion of reaction, solvent was removed under reduced pressure, diluted with water (20 mL) and extracted with CH2Cl2 (20 mL×3). Combined organic layer was washed with brine solution, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford crude product which was washed with diethyl ether and dried to afford 214 1-cyclopropyl-4-(4-nitrophenyl)piperazine (450 mg). (0348) LCMS: 248 [M+1]+

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; giraFpharma LLC; Chakravarty, Sarvajit; PHAM, Son Minh; Kankanala, Jayakanth; AGARWAL, Anil Kumar; PUJALA, Brahmam; SONI, Sanjeev; ARYA, Satish K.; PALVE, Deepak; KUMAR, Varun; (360 pag.)US2019/106436; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 3 (General procedure A); 2-(4-Cyclopropylpiperazin-1-yl)-6-methoxybenzothiazole, hydrochloride; A mixture of 2-chloro-6-methoxybenzothiazole (0.20 g, 1.0 mmol) and 1-cyclopropyl- piperazine (0.25 g, 2.0 mmol) was stirred at 120 0C overnight. The reaction mixture was allowed to cool and dissolved in a mixture of ethyl acetate a NaHCO3 solution. The phases were separated and the organic phase was washed with water (3 x) and then extracted with 0.25 M hydrochloric acid (20 ml_). The acidic aqueous extract was concentrated and re- evaporated with ethanol. The residue was crystallized from a mixture of ethanol and ethyl acetate to give 60 mg (18 %) of 2-(4-cyclopropylpiperazin-1-yl)-6-methoxybenzothiazole, hydrochloride. 1H-NMR (400MHz, DMSO-d6) delta 11.3 (brs, 1 H), 7.48 (d, 1 H), 7.45 (d, 1 H), 6.93 (dd, 1 H), 4.18-4.06 (m, 2H), 3.89-3.75 (m, 5H), 3.68-3.52 (m, 2H), 3.44-3.33 (m, 2H), 2.94-2.86 (m, 1 H), 1.21-1.15 (m, 2H), 0.85-0.79 (m, 2H).

20327-23-5, 20327-23-5 1-Cyclopropylpiperazine 4742004, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; NOVO NORDISK A/S; WO2007/110364; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To 80 mg (0.19 mmol) E-8 in 1 mL dioxane is added 0.12 g (0.93 mmol) 1-cyclopropyl-piperazine and 26 muL (0.19 mmol) triethylamine and the reaction mixture is stirred for 3 h at 80C. A 1/1 acetonitrile/water mixture is added and the reaction mixture is purified by RP chromatography (C18). Yield: 49 mg (51%). HPLC-MS: M+H = 521; tR = 1.26 min.

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; The designation of the inventor has not yet been filed; EP2546249; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

A 100 mL round bottom flask was charged with 1.84 g (lOmmol) of compound II, 1.26 g (lOmmol) of compound III-2 and 20 mL of dry THF, and the resulting mixture was stirred under cooling with ice-water bath, After adding 2.48 g (12 mmll) of DCC, stirring was continued at room temperature overnight. TLC shows the completion of the reaction. The reaction mixture was poured into ice water, stirred, extracted with 50 mL of X3 dichloromethane, the combined organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, the solvent was evaporated on a rotary evaporator, The resulting residue was purified by column chromatography to give product 1-2 as a white solid.

20327-23-5, 20327-23-5 1-Cyclopropylpiperazine 4742004, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; Zhejiang Pharmaceutical College; Guo Zhanghua; (6 pag.)CN104326974; (2017); B;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3-Cyclobutyl-1-cyclohexyl-4-(6-fluoro-pyridin-3-yl)-1H-pyrazolo[3,4-]pyridine-6-carboxylic acid (200 mg, 0.51 mmol) was heated together with 1-cyclopropylpiperazine ([20327- 23-5], 64 muL, 0.53 mmol) and DIPEA (110 muL, 0.64 mmol) in NMP (2 mL) at 100 C for 18 hours. The mixture was diluted with EtOAc and water. Isolation of the organic layer and subsequent concentration yielded the titled compound., 20327-23-5

As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; ABBVIE S.A.R.L; GALAPAGOS NV; AKKARI, Rhalid; ALVEY, Luke Jonathan; BOCK, Xavier Marie; BROWN, Brian S.; CLAES, Pieter Isabelle Roger; COWART, Marlon D.; DE LEMOS, Elsa; DESROY, Nicolas; DUTHION, Beranger; GFESSER, Gregory A.; GOSMINI, Romain Luc Marie; HOUSSEMAN, Christopher Gaetan; JANSEN, Koen Karel; JI, Jianguo; KYM, Philip R.; LEFRANCOIS, Jean-Michel; MAMMOLITI, Oscar; MENET, Christel Jeanne Marie; MERAYO, Nuria Merayo; NEWSOME, Gregory John Robert; PALISSE, Adeline Marie Elise; PATEL, Sachin V.; PIZZONERO, Mathieu Rafael; SHRESTHA, Anurupa; SWIFT, Elizabeth C.; VAN DER PLAS, Steven Emiel; WANG, Xueqing; DE BLIECK, Ann; (1004 pag.)WO2017/60874; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

A solution of DIPEA (690 mul, 3.97 mmol) and 1-cyclopropylpiperazine (500 mg, 3.97 mmol) in acetonitrile (5 ml) was added to a solution of 2-chloro-5-nitropyridine (631 mg, 3.97 mmol) in acetonitrile (10 ml). The mixture was stirred at rt for 4 hours and then concentrated to dryness. The residue was diluted with DCM and 2M sodium carbonate solution (aq). The organic phase was dried and concentrated to give a yellow solid (912 mg, 93%). 1H NMR (400 MHz, DMSO-cfe) delta ppm 0.31 – 0.49 (m, 4 H), 1.65 (it, ./=6.70, 3.38 Hz, 1 H), 2.52 – 2.69 (m, 4 H), 3.61 – 3.82 (m, 4 H), 6.95 (d, 7=9.62 Hz, 1 H), 8.21 (dd, 7=9.62, 2.75 Hz, 1 H), 8.95 (d, 7=2.75 Hz, 1 H); m/z (ES+APCI)+: 249 [M+H]+., 20327-23-5

As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; MEDICAL RESEARCH COUNCIL; WO2009/122180; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

In a 5 ml_ glass microwave vial equipped with a magnetic stirring bar and nitrogen flow at room temperature was placed the methyl 4-bromo-1-(4-bromo-5- (isopropylthio)thiazol-2-yl)-3-methyl-1 H-pyrazole-5-carboxylate prepared as described above with respect to Compound 1 (150 mg, 0.330 mmol), the 1-cyclopropylpiperazine (42 mg, 0.33 mmol), Cs2C03(537 mg, 1.65 mmol), XantPhos (19 mg, 0.033 mmol) and dioxane (3 ml_). Nitrogen was bubbled in the solvent for 10 minutes followed by the addition of the catalyst RuPhos Pd G1 (27 mg, 0.033 mmol). The vial was capped and placed in an oil bath at 105 C for 16 h. The product was purified by flash chromatography (dry packing) on silica gel using a gradient 0 to 10% EtOAc in hexanes to give the title compound (28 mg, 0.055 mmol, 17%) as a yellow oil. MS (m/z): 500.0 [M+1]+., 20327-23-5

20327-23-5 1-Cyclopropylpiperazine 4742004, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; BANTAM PHARMACEUTICAL, LLC; SIDDIQUI, Arshad, M.; CIBLAT, Stephane; DERY, Martin; CONSTANTINEUA-FORGET, Lea; GRAND-MAITRE, Chantal; BRUNEAU-LATOUR, Nicolas; SHIPPS, Gerald, W.; COOPER, Alan, B.; OZA, Vibha; KOSTURA, Matthew, W.; LUTHER, Michael; LEVINE, Jedd; (174 pag.)WO2018/102453; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

In a 5 ml_ glass microwave vial equipped with a magnetic stirring bar and nitrogen flow at room temperature was placed the methyl 4-bromo-1-(4-bromo-5- (isopropylthio)thiazol-2-yl)-3-methyl-1 H-pyrazole-5-carboxylate prepared as described above with respect to Compound 1 (150 mg, 0.330 mmol), the 1-cyclopropylpiperazine (42 mg, 0.33 mmol), Cs2C03(537 mg, 1.65 mmol), XantPhos (19 mg, 0.033 mmol) and dioxane (3 ml_). Nitrogen was bubbled in the solvent for 10 minutes followed by the addition of the catalyst RuPhos Pd G1 (27 mg, 0.033 mmol). The vial was capped and placed in an oil bath at 105 C for 16 h. The product was purified by flash chromatography (dry packing) on silica gel using a gradient 0 to 10% EtOAc in hexanes to give the title compound (28 mg, 0.055 mmol, 17%) as a yellow oil. MS (m/z): 500.0 [M+1]+., 20327-23-5

20327-23-5 1-Cyclopropylpiperazine 4742004, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; BANTAM PHARMACEUTICAL, LLC; SIDDIQUI, Arshad, M.; CIBLAT, Stephane; DERY, Martin; CONSTANTINEUA-FORGET, Lea; GRAND-MAITRE, Chantal; BRUNEAU-LATOUR, Nicolas; SHIPPS, Gerald, W.; COOPER, Alan, B.; OZA, Vibha; KOSTURA, Matthew, W.; LUTHER, Michael; LEVINE, Jedd; (174 pag.)WO2018/102453; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

Intermediate 33: Step a 1-(6-(4-Cyclopropylpiperazin-1-yl)pyridin-3-yl)ethanone A solution of 1-cyclopropylpiperazine (0.162 g, 1.29 mmol), 1-(6-chloropyridin-3-yl)ethanone (0.200 g, 1.29 mmol) and DMSO (0.2 mL) was heated to 100 C. overnight. The reaction was cooled to room temperature, ethyl acetate was added and the reaction mixture was filtered to give the title compound as a solid., 20327-23-5

As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; ZHANG, Yan; Tounge, Brett Andrew; Wang, Aihua; Hawkins, Michael; Leonard, Kristi Anne; Barbay, Joseph Kent; Maharoof, Umar S.M.; US2012/129843; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics